4820 Richard Road SW
AB T3E 6L1
Canada - Map
Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing RVX-208, a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimers disease, peripheral artery disease, and chronic kidney disease. Resverlogix Corp. is headquartered in Calgary, Canada.
|Mr. Donald J. McCaffrey ,
Co-Founder, Chairman, Chief Exec. Officer, Pres and Sec.
|Mr. Aaron Bradley Cann C.A., CBV,
Chief Financial Officer
|Mr. Kenneth Eugene Lebioda BA,
Sr. VP of Bus. Devel.
|Dr. Jan O. Johansson M.D., Ph.D.,
Sr. VP of Medical Affairs
|Dr. Michael Sweeney M.D.,
Sr. VP of Clinical Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|